Posts Tagged ‘malignant pleural mesothelioma’

IMRT proves effective mesothelioma treatment, study finds

25 Jul 2017 by under Research/Treatment
Przekrój ciała Pacjenta z rozkładem dawki promieniowania z nowotworem Głowy i Szyji leczonego techniką IMRT. 100x100 IMRT proves effective mesothelioma treatment, study finds


Intensity modulated radiation therapy (IMRT) is the most advanced type of radiation, allowing for even greater regulation of radiation beams than was possible in 3D planning. It’s a “sophisticated form of 3D planning,” according to OncoLink, and it is used regularly to treat a variety of cancers, including prostate cancer, gastrointestinal cancers, brain cancers and lung cancers.

IMRT has become increasingly important in the treatment of , a rare cancer caused by asbestos exposure that affects the lining of internal organs, but until recently, its benefits had never been proven, according to Surviving . Dr. Kenneth Rosenzweig’s new study published in the Annals of Translational Medicine concludes IMRT at an experienced institution has led to improved mesothelioma outcomes and is “both feasible and effective” as a treatment option for (more…)

Usefulness of second-line pleural mesothelioma treatment ‘uncertain at best;’ clinical trials vital

31 Jan 2017 by under Research/Treatment

1280px Chemotherapy vials 2 edited1 100x100 Usefulness of second line pleural mesothelioma treatment uncertain at best; clinical trials vitalCurrently no accepted second-line treatment—therapy used when a cancer reoccurs—exists for due to inconclusive evidence of any notable life-extending benefits.

Pleural , a cancer affecting the lining of a patient’s lungs and associated with exposure to asbestos, is deadly, with most patients dying a year to two years after diagnosis. Surviving Mesothelioma reports three researchers from England and Italy are calling for a redesign of studies testing the efficacy of second-line treatment in pleural mesothelioma patients to definitively determine if the additional treatment will extend patients’ lives. (more…)

Mesothelioma cell growth may be slowed by drug already approved by FDA to treat alcoholism

26 Apr 2014 by under Research/Treatment

cancer stem cell 100x100 Mesothelioma cell growth may be slowed by drug already approved by FDA to treat alcoholismResearchers from in Detroit, Mich., have discovered a drug already approved by the U.S. Food and Drug Administration (FDA) to treat alcoholism may play an important role in halting the growth of (MPM). Mesothelioma is an aggressive form of cancer linked to asbestos exposure, which most often affects the lining of the lungs (pleural) or the abdomen (peritoneal). (more…)

COMMAND clinical trial treating patients with malignant pleural mesothelioma

2 Oct 2013 by under Events, News, Research/Treatment

cancer stem cell 100x100 COMMAND clinical trial treating patients with malignant pleural mesotheliomaDrug manufacturer , Inc., has initiated a registration-directed, double-blind, placebo-controlled clinical trial for patients with malignant pleural mesothelioma. The trial is a registration-directed trial for VS-6063, Verastem’s lead cancer stem cell inhibitor defactinib , and will target killing cancer stem cells. The clinical trial is called Control of Mesothelioma with MAiNtenance Defactinib, or . (more…)

MicroRNA technology provides early diagnosis of mesothelioma

5 May 2009 by under News, Research/Treatment

I came across a news story today about Rosetta Genomics, a company that is pioneering the technology of microRNA-based diagnostic tests and therapeutic tools. According to the company web site, microRNAs, or miRNAs, are a recently discovered group of short non-coding genes that regulate the expression of other genes. What this means to the lay person is that by looking at the very specific markers in these genes, physicians can more accurately identify cancer, predict outcomes and help guide treatment.

Among Rosetta’s products is miRview™ meso, which is described as a “cutting edge molecular diagnostic test that uses microRNA to differentiate malignant from peripheral adenocarcinomas of the lung or metastatic carcinomas involving the lung and pleura.” According to the company, accuracy for this test has been 95 percent for sensitivity and 96 percent for specificity in identifying mesothelioma.

Obviously, the sooner mesothelioma can be identified, the sooner a correct course of treatment can begin.

You can watch a video from the company’s web site with 3-D animation that demonstrates how microRNA diagnostics work to detect mesothelioma.

You can also download a brochure that explains how miRview™ meso works in more detail.

According to RNAi News, a publication that spotlights technology for functional genomics, this week Rosetta Genomics announced that it has closed a deal with Prometheus Laboratories that will give Prometheus the U.S. market rights to Rosetta’s three microRNA-based diagnostics, which includes the meso diagnostic. The other two products are miRview Mets, which is designed to determine the source of cancers of unknown primary origin, and miRview Squamous, which is designed to differentiate squamous from non-squamous non-small cell lung cancer.

The deal will provide Rosetta with funding for research and development, and the company will receive royalties on net product sales from Prometheus, RNAi News reports. The companies also will jointly develop two additional miRNA-based gastroenterology diagnostics.

Mesothelioma is a rare cancer caused by exposure that most often affects the lining of the lungs, although it can also affect the lining of the stomach and/or the heart.